Incretins in fibrocalculous pancreatic diabetes: A unique subtype of pancreatogenic diabetes. Issue 6 (16th December 2020)

• Record Type: Journal Article
• Authors: Ghosh, Ipsita; Mukhopadhyay, Pradip; Das, Kshaunish; Anne M, Beatrice; Ali Mondal, Samim; Basu, Madhurima; Nargis, Titli; Pandit, Kaushik; Chakrabarti, Partha; Ghosh, Sujoy
• Is Part Of: Journal of diabetes. Volume 13:Issue 6(2021)
• Page Start: 506
• Page End: 511
• Publication Date: 2020-12-16
• Subjects: FCPD -- fibrocalculous pancreatic diabetes -- incretins -- pancreatogenic diabetes; FCPD -- 纤维结石性胰腺糖尿病 -- 肠泌素 -- 胰源性糖尿病。; Diabetes -- Periodicals; 618.3646005
• DOI: 10.1111/1753-0407.13139
• Languages: English
• ISSNs: 1753-0393

Abstract

Abstract: Background: Studies evaluating endocrine and exocrine functions in fibrocalculous pancreatic diabetes (FCPD) are scarce. Methods: Insulin, C‐peptide, glucagon, incretin hormones (glucagon‐like peptide 1 [GLP‐1] and gastric inhibitory peptide [GIP]), and dipeptidyl peptidase IV (DPP‐IV) were estimated in patients with FCPD (n = 20), type 2 diabetes mellitus (T2DM) (n = 20), and controls (n = 20) in fasting and 60 minutes after 75 g glucose. Results: Fasting and post‐glucose C‐peptide and insulin in FCPD were lower than that of T2DM and controls. Plasma glucagon decreased after glucose load in controls (3.72, 2.29), but increased in T2DM (4.01, 5.73), and remained unchanged in FCPD (3.44, 3.44). Active GLP‐1 (pmol/L) after glucose load increased in FCPD (6.14 to 9.72, P = <.001), in T2DM (2.87 to 4.62, P < .001), and in controls (3.91 to 6.13, P < .001). Median active GLP‐1 in FCPD, both in fasting and post‐glucose state (6.14, 9.72), was twice that of T2DM (2.87, 4.62) and 1.5 times that of controls (3.91, 6.13) ( P < .001 for all). Post‐glucose GIP (pmol/L) increased in all: FCPD (15.83 to 94.14), T2DM (21.85 to 88.29), and control (13.00 to 74.65) ( P < .001 for all). GIP was not different between groups. DPP‐IV concentration (ng/mL) increased in controls (1578.54, 3012.00) and FCPD (1609.95, 1995.42), but not in T2DM (1204.50, 1939.50) ( P = .131). DPP‐IV between the three groups was not different. Fecal elastase was low in FCPD compared with T2DM controls. Conclusions: In FCPD, basal C‐peptide and glucagon are low, and glucagon does not increase after glucose load. GLP‐1, but not GIP, in FCPD increases 1.5 to 2 times as compared with T2DM and controls (fasting and post glucose) without differences in DPP‐IV. Abstract : Highlights Incretins in pancreatogenic diabetes have been studied in chronic pancreatitis; however, incretins in fibrocalculous pancreatic diabetes (FCPD), a unique form of pancreatogenic diabetes, have not been explored previously. This study would significantly help in incretin biology in FCPD and may help bridge the knowledge gap in current understanding. 摘要: 背景: 评价纤维结石性胰腺糖尿病(FCPD)内分泌和外分泌功能的研究很少。 方法: 测定FCPD组(n=20)、2型糖尿病(T2 DM)组(n=20)和对照组(n=20)空腹和75g葡萄糖后60min的胰岛素、C肽、胰高血糖素、肠泌素(胰高血糖素样肽1[GLP‐1]和胃抑制肽[GIP])、二肽基肽酶IV(DPP‐IV)水平。 结果: FCPD组空腹和糖负荷后C肽、胰岛素水平均低于T2 DM组和对照组。对照组糖负荷后胰高血糖素(pmol/L)降低(3.72; 2.29); T2 DM组升高(4.01; 5.73); FCPD组(3.44; 3.44)无明显变化。FCPD组(6.14~9.72; P=<0.001)、T2 DM组(2.87~4.62; P<0.001)和对照组(3.91~6.13; P<0.001)糖负荷后活性GLP‐1(pmol/L)升高。FCPD组空腹和糖负荷后GLP‐1(pmol/L)活性中位数(6.14; 9.72)是T2 DM组(2.87; 4.62)的两倍; 是对照组(3.91; 6.13)的1.5倍(P<0.001)。糖负荷后GIP(pmol/L)在所有组别中都升高:FCPD(15.83~94.14)、T2DM(21.85~88.29)、对照组(13.00~74.65), P<0.01。不同组间GIP差异无统计学意义。对照组(1578.54, 3012.00)和FCPD组(1609.95, 1995.42)的DPP‐IV浓度(ng/mL)升高; 而T2 DM组(1204.50, 1939.50)的DPP‐IV浓度无明显变化(P=0.131)。DPP‐IV于三组间差异无统计学意义。FCPD组中粪弹性蛋白酶低于T2 DM组对照组。 结论: FCPD患者糖负荷后基础C肽和胰高血糖素降低; 在糖负荷后胰高血糖素不升高。FCPD的GLP‐1; 而不是GIP; 与T2 DM和对照组(空腹和糖负荷后)相比升高了1.5‐2倍; 而DPP‐IV没有差异